ESTRO 2025 - Abstract Book

S4318

RTT - Treatment planning, OAR and target definitions

ESTRO 2025

Results: Since implementing ATS-Lite in 2023, five rectal cancer patients (25 fractions each) and seven esophageal cancer patients (three with 28 fractions, four with 23 fractions) were treated. Treatment times were recorded in 73% of the 301 fractions (Figure 2). Median treatment duration was 21:09 minutes for rectal patients and 23:00 minutes for esophageal patients, with maximum times of 26:50 minutes and 38:00 minutes, respectively, due to occasional patient repositioning. After deformable contour propagation, minor manual adjustments were needed in 45 of 125 fractions (36%) for rectal patients, while no adjustments were required for esophageal patients as the contours were accurately propagated.